首页> 美国卫生研究院文献>PLoS Clinical Trials >Generation of Novel Bone Forming Cells (Monoosteophils) from the Cathelicidin-Derived Peptide LL-37 Treated Monocytes
【2h】

Generation of Novel Bone Forming Cells (Monoosteophils) from the Cathelicidin-Derived Peptide LL-37 Treated Monocytes

机译:从Cathelicidin衍生肽LL-37处理的单核细胞中生成新的骨形成细胞(单核细胞)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundBone generation and maintenance involve osteoblasts, osteoclasts, and osteocytes which originate from unique precursors and rely on key growth factors for differentiation. However, an incomplete understanding of bone forming cells during wound healing has led to an unfilled clinical need such as nonunion of bone fractures. Since circulating monocytes are often recruited to sites of injury and may differentiate into various cell types including osteoclasts, we investigated the possibility that circulating monocytes in the context of tissue injury may also contribute to bone repair. In particular, we hypothesized that LL-37 (produced from hCAP-18, cathelicidin), which recruits circulating monocytes during injury, may play a role in bone repair.
机译:背景技术骨骼的生成和维持涉及成骨细胞,破骨细胞和骨细胞,它们源自独特的前体,并依赖关键的生长因子进行分化。但是,在伤口愈合过程中对骨形成细胞的不完全了解导致未满足的临床需求,例如骨折不愈合。由于循环单核细胞通常被募集到损伤部位,并且可能分化为包括破骨细胞在内的各种细胞类型,因此我们研究了在组织损伤的情况下循环单核细胞也可能有助于骨骼修复的可能性。特别是,我们假设在损伤期间募集循环单核细胞的LL-37(由hCAP-18,cathelicidin生产)可能在骨修复中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号